Why Pegfilgrastim Biosimilars Are Gaining Global Momentum

Cancer treatment has advanced significantly over the past decade, but chemotherapy-induced complications remain a major challenge for patients and healthcare providers. One of the most serious complications is neutropenia, a condition characterized by dangerously low levels of neutrophils, which increases the risk of life-threatening infections. Pegfilgrastim, a long-acting granulocyte colony-stimulating factor (G-CSF), plays a critical role in preventing neutropenia by stimulating white blood cell production.

As the cost of biologic therapies continues to strain healthcare systems, biosimilars have emerged as a cost-effective and clinically equivalent alternative. The Pegfilgrastim Biosimilars Market is experiencing steady growth, driven by the rising prevalence of leukemia, increasing cancer chemotherapy usage, and strong regulatory support for biosimilars across major markets.

In 2025, global leukemia cases reached approximately 0.62 million, highlighting the growing need for supportive oncology therapies. With this alarming rise, the Pegfilgrastim Biosimilars Market is expected to grow at a CAGR of 7.00% from 2026 to 2035, reaching a forecast value of USD 1.22 million by 2035.

Pegfilgrastim Biosimilars Market Overview

Pegfilgrastim biosimilars are biologic medicines designed to be highly similar to the reference pegfilgrastim product in terms of safety, efficacy, and quality. They are primarily used to reduce the incidence of febrile neutropenia in patients undergoing myelosuppressive chemotherapy.

Key Market Snapshot

• Leukemia Cases (2025): ~0.62 Million

• Market CAGR (2026–2035): 7.00%

• Forecast Market Value (2035): USD 1.22 Million

• Primary Use: Prevention of chemotherapy-induced neutropenia

• Key End Users: Hospitals and oncology centers

The Pegfilgrastim Biosimilars Market benefits from strong clinical evidence, growing physician confidence, and favorable reimbursement policies in several regions.

Key Growth Drivers of the Pegfilgrastim Biosimilars Market

1. Rising Prevalence of Leukemia and Other Cancers

The global burden of leukemia and solid tumors is increasing due to aging populations, lifestyle changes, and improved diagnostic capabilities. Chemotherapy remains a cornerstone of cancer treatment, driving demand for supportive therapies such as pegfilgrastim biosimilars.

2. Increasing Adoption of Cost-Effective Biosimilars

Biosimilars offer significant cost savings compared to originator biologics, making them attractive to:

• Healthcare providers

• Payers and insurance companies

• Public healthcare systems

This economic advantage is a key factor accelerating market penetration.

3. Expanding Chemotherapy Usage Worldwide

With cancer incidence rising globally, chemotherapy utilization is increasing across developed and emerging economies, boosting demand for neutropenia prophylaxis.

4. Favorable Regulatory Pathways

Regulatory agencies in North America, Europe, and parts of Asia Pacific have established clear guidelines for biosimilar approval, encouraging pharmaceutical companies to invest in pegfilgrastim biosimilar development.

5. Growing Awareness Among Clinicians

Improved education and real-world evidence are increasing physician confidence in prescribing biosimilars, further supporting market growth.

Key Trends Shaping the Pegfilgrastim Biosimilars Market

1. Shift Toward Long-Acting G-CSF Biosimilars

Pegfilgrastim biosimilars are preferred over short-acting filgrastim due to:

• Once-per-cycle dosing

• Improved patient compliance

• Reduced hospital visits

2. Expansion in Emerging Markets

Asia Pacific and Latin America are witnessing rapid adoption of biosimilars due to:

• Cost-sensitive healthcare systems

• Increasing oncology treatment access

3. Strategic Partnerships and Licensing Agreements

Pharmaceutical companies are entering licensing and distribution agreements to expand geographic reach and accelerate commercialization.

4. Growing Role of Online and Retail Pharmacies

Digital pharmacy platforms are improving accessibility, especially for outpatient oncology care.

Pegfilgrastim Biosimilars Market Segmentation Analysis

By Indication Type

Neutropenia

• Largest market share

• Primary indication for pegfilgrastim biosimilars

• Strong demand from oncology settings

Hematopoietic Subsyndrome

• Used in radiation-induced marrow suppression

• Niche but clinically important segment

Others

• Includes off-label and investigational uses

By Product Type

The market includes a diverse range of biosimilar formulations, such as:

• MK-6302

• Peg G-CSF

• PEG Neutrogena

• Grasustek

• LA-EP2006

• R-TPR-029

• Filgrastim / PEG-GCSF

• Others

Product differentiation is largely based on formulation, delivery systems, and regulatory approvals.

By Application

Chemotherapy-Induced Neutropenia

• Dominant application segment

• Essential supportive care in oncology

Transplantation

• Used in bone marrow and stem cell transplantation

• Supports faster neutrophil recovery

Others

• Includes investigational and specialty applications

By Distribution Channel

Hospital-Based Pharmacies

• Largest distribution channel

• Integrated with oncology treatment centers

Retail Pharmacies

• Increasing role in outpatient cancer care

Online Pharmacies

• Fastest-growing channel

• Improved convenience and accessibility

Regional Analysis of the Pegfilgrastim Biosimilars Market

North America

• Strong regulatory framework for biosimilars

• High cancer treatment volumes

• Increasing payer-driven adoption

Europe

• Early adopter of biosimilars

• Strong government support and cost-containment policies

Asia Pacific

• Fastest-growing regional market

• Expanding oncology infrastructure

• Rising domestic biosimilar manufacturers

Latin America

• Gradual uptake driven by healthcare reforms

• Growing awareness of biosimilar benefits

Middle East and Africa

• Emerging market

• Increasing access to oncology treatments

Competitive Landscape: Key Players in the Pegfilgrastim Biosimilars Market

The Pegfilgrastim Biosimilars Market is moderately competitive, with both global pharmaceutical giants and regional manufacturers participating.

Companies Covered

• Merck & Co., Inc.

• Zydus Lifesciences Limited

• Ratiopharm GmbH

• Jiangsu Hengrui Pharmaceuticals Co., Ltd.

• Biocon Limited

• Dr. Reddy’s Laboratories Ltd.

• Pfizer Inc.

• Emcure Pharmaceuticals Limited

• USV Private Limited

• Apotex Pty Ltd

• Kyowa Kirin Co., Ltd.

• Lupin Limited

Key Competitive Strategies

• Product launches and regulatory approvals

• Strategic partnerships and licensing

• Expansion into emerging markets

Challenges in the Pegfilgrastim Biosimilars Market

Despite strong growth prospects, the market faces several challenges:

• High development and manufacturing costs

• Complex regulatory requirements

• Physician hesitancy in certain regions

• Competitive pricing pressures

Addressing these challenges will be critical for long-term market sustainability.

Future Outlook: Pegfilgrastim Biosimilars Market Through 2035

The Pegfilgrastim Biosimilars Market is expected to experience steady growth through 2035, supported by:

• Rising global cancer burden

• Increasing acceptance of biosimilars

• Continued expansion of oncology services

Future opportunities will likely focus on:

• Improved delivery systems (on-body injectors)

• Expansion into underserved markets

• Integration into value-based cancer care models

Uncover More Reports

Genomics Market

Legal Marijuana Market

Telemedicine Market

Skincare Devices Market

About Us:

Expert Market Research is a leading market research firm delivering data-driven insights to the pharmaceutical, biotechnology, and medical device industries. Our comprehensive research solutions include market research reports, providing in-depth analysis of industry trends and competitive landscapes; drug pipeline reports, tracking drug development progress, clinical trials, and regulatory approvals; epidemiology reports, offering detailed disease prevalence and patient population studies; and patent reports, assessing intellectual property landscapes and innovation trends, among others.

Leveraging proprietary data, advanced analytics, and expert methodologies, we help businesses navigate complex markets, optimize strategies, and drive innovation. We empower clients with actionable intelligence, enabling them to make informed decisions and stay ahead in the rapidly evolving healthcare sector.

Media Contact:

Company Name: Claight Corporation
Contact Person: Roshan Kumar, Digital Marketing
Email: sales@expertmarketresearch.com
Toll-Free Number: US +1-415-325-5166 | UK +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA
Website: www.expertmarketresearch.com